Anti-inflammatory effects of Tat-Annexin protein on ovalbumin-induced airway inflammation in a mouse model of asthma.
Chronic airway inflammation is a key feature of bronchial asthma. Annexin-1 (ANX1) is an anti-inflammatory protein that is an important modulator and plays a key role in inflammation. Although the precise action of ANX1 remains unclear, it has emerged as a potential drug target for inflammatory diseases such as asthma. To examine the protective effects of ANX1 protein on ovalbumin (OVA)-induced asthma in animal models, we used a cell-permeable Tat-ANX1 protein. Mice sensitized and challenged with OVA antigen had an increased amount of cytokines and eosinophils in their bronchoalveolar lavage (BAL) fluid. However, administration of Tat-ANX1 protein before OVA challenge significantly decreased the levels of cytokines (interleukin (IL)-4, IL-5, and IL-13) and BAL fluid in lung tissues. Furthermore, OVA significantly increased the activation of mitogen-activated protein kinase (MAPK) in lung tissues, whereas Tat-ANX1 protein markedly reduced phosphorylation of MAPKs such as extracellular signal-regulated protein kinase, p38, and stress-activated protein kinase/c-Jun N-terminal kinase. These results suggest that transduced Tat-ANX1 protein may be a potential protein therapeutic agent for the treatment of lung disorders including asthma.
Department of Biomedical Science, Hallym University, Chunchon, Republic of Korea.
Sun Hwa
SH
Lee
Dae Won
DW
Kim
Hye Ri
HR
Kim
Su Jung
SJ
Woo
So Mi
SM
Kim
Hyo Sang
HS
Jo
Seong Gyu
SG
Jeon
Sung-Woo
SW
Cho
Jong Hoon
JH
Park
Moo Ho
MH
Won
Jinseu
J
Park
Won Sik
WS
Eum
Soo Young
SY
Choi
D000818:Animals; D017305:Annexin A1 / Q000008:administration & dosage / Q000627:therapeutic use*; D017302:Annexins / Q000008:administration & dosage / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000517:prevention & control; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004195:Disease Models, Animal; D005260:Female; D015696:Gene Products, tat / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use*
D017305:Annexin A1; D017302:Annexins; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D015696:Gene Products, tat; D011993:Recombinant Fusion Proteins; C571041:Tat-ANX1 fusion protein; D010047:Ovalbumin